Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination cell-based biologic therapy consisting of human placenta-derived mesenchymal stem cells (hP-MSCs) and hyaluronic acid (HA). The hyaluronic acid component serves as a biocompatible scaffold or carrier, enhancing cell retention and survival at the site of administration, while also potentially providing therapeutic lubrication in joint applications. The mesenchymal stem cells are believed to exert their effects through paracrine mechanisms, releasing a variety of pro-regenerative, anti-inflammatory, and immunomodulatory factors. This combination is primarily investigated for regenerative medicine applications, including the treatment of knee osteoarthritis via intra-articular injection and endometrial injury or thin endometrium via intrauterine delivery using hydrogel formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on placenta-derived mesenchymal stem cells + hyaluronic acid.